Apellis Pharmaceuticals Inc
(STU:1JK)
€
25.73
-0.175 (-0.68%)
Market Cap: 3.15 Bil
Enterprise Value: 3.25 Bil
PE Ratio: 0
PB Ratio: 12.89
GF Score: 25/100 Apellis Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript
Sep 08, 2023 / 01:30PM GMT
Release Date Price:
€39.8
(+0.51%)
Derek Christian Archila
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
All right, everyone. I think we'll get started with our next fireside discussion. My name is Derek Archila. I'm one of the senior biotech analyst here at Wells. Very happy to have Apellis Pharmaceuticals and the team. Got Cedric, the CEO; and we got Tim, the CFO here for the discussion. Gentlemen, thanks so much for joining us.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Thank you, Derek.
Derek Christian Archila
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
All right. Great. Good to have you again. Well, I'm going to turn it over to Cedric to kind of give a kind of state of the business currently and then we can kind of dive into questions afterwards. But Cedric, I'll turn it over to you.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Thank you, Derek. So
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot